摘要
目的:探讨氯氮平联合帕利哌酮对难治性精神分裂症患者进行治疗的效果及不良反应。方法:选择广州市中西医结合医院2013年11月—2015年1月收治的难治性精神分裂症患者120例,按随机数字表法分为观察组和对照组,每组各60例。对照组患者给予氯氮平进行治疗,观察组患者给予氯氮平联合帕利哌酮进行治疗,采用阳性和阴性症状量表评分评价2组患者的疗效及不良反应。结果:观察组患者的总有效率为85.00%(51/60),明显高于对照组的50.00%(30/60),差异有统计学意义(P<0.05);观察组患者生活质量评分为(3.11±10.90)分,对照组为(2.71±0.67)分;观察组患者的精神症状改善评分为(38.11±10.97)分,对照组为(32.76±12.37)分;观察组患者精神分裂控制时间为(11.87±2.38)d,对照组为(17.29±3.21)d,差异均有统计学意义(P<0.05)。观察组患者发生体质量增加4例,对照组为12例,差异有统计学意义(P<0.05)。2组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:应用氯氮平联合帕利哌酮可显著改善难治性精神分裂症患者的临床症状,不良反应较低,值得临床推广。
OBJECTIVE： To probe into the effects and adverse reactions of clozapine combined with paliperidone in treatment of refractory schizophrenia.METHODS： 120 cases of refractory schizophrenia admitted into Guangzhou Hospitals of Traditional Chinese and Western Medicine from Nov.2013 to jan.2015 were selected to be divided into observation group and control group,with 60 cases in each.The control group were treated with clozapine,while the observation group received clozapine combined with paliperidone; the efficacy and adverse reactions in two groups were evaluated by positive and negative symptom assessment scale score.RESULTS： The total efficacy of observation group was 85.00%（ 51 /60）,significantly higher than that of control group 50.00%（ 30 /60）,with statistically significant difference（ P〈0.05）.In observation group,the quality of life score,the improvement score of psychiatric symptoms and the control time of schizophrenia were respectively（ 3.11 ± 10.90） scores,（ 38.11 ± 10.97） scores and（ 11.87 ± 2.38） d,while in control group were respectively（ 2.71 ± 0.67） scores,（ 32.76 ± 12.37） scores and（ 17.29 ± 3.21） d; with statistically significance（ P〈0.05）.There were 4 cases with gain of body mass in observation group,and control group were 12 cases,the difference was significant（ P〈0.05）.There was no significant difference in the incidence of adverse reactions between two group of patients（ P〉0.05）.CONCLUSIONS： Clozapine combined with paliperidone can improve the clinical symptoms of refractory schizophrenia,with few adverse reactions.It is worthy of clinical promotion.
出处
《中国医院用药评价与分析》
2016年第2期172-173,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
